Modelling bone metastasis in spheroids to study cancer progression and screen cisplatin efficacy

Abstract

Most bone metastases are caused by primary breast or prostate cancer cells settling in the bone microenvironment, affecting normal bone physiology and function and reducing 5-year survival rates to 10% and 6%, respectively. To expedite clinical availability of novel and effective bone metastases treatments, reliable and predictive in vitro models are urgently required to screen for novel therapies as current in vitro 2D planar mono-culture models do not accurately predict the clinical efficacy. We herein engineered a novel human in vitro 3D co-culture model based on spheroids to study dynamic cellular quantities of (breast or prostate) cancer cells and human bone marrow stromal cells and screen chemotherapeutic efficacy and specificity of the common anticancer drug cisplatin. Bone metastatic spheroids (BMSs) were formed rapidly within 24 h, while the morphology of breast versus prostate cancer BMS differed in terms of size and circularity upon prolonged culture periods. Prestaining cell types prior to BMS formation enabled confocal imaging and quantitative image analysis of in-spheroid cellular dynamics for up to 7 days of BMS culture. We found that cancer cells in BMS proliferated faster and were less susceptible to cisplatin treatment compared to 2D control cultures. Based on these findings and the versatility of our methodology, BMS represent a feasible 3D in vitro model for screening of new bone cancer metastases therapies.

References

[1] ColemanRE, Croucher PI, PadhaniAR, et al. Bone metastases. Nat Rev Dis Primers. 2020; 6(1):83.

[2] TsukamotoS, KidoA, TanakaY, et al. Current overview of treatment for metastatic bone disease. Curr Oncol. 2021; 28(5):3347-3372.

[3] SvenssonE, Christiansen CF, UlrichsenSP, RørthMR, Sørensen HT. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open. 2017; 7(9):e016022.

[4] CastanedaM, den Hollander P, KuburichNA, RosenJM, ManiSA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022; 87:17-31.

[5] EspositoM, GuiseT, KangY. The biology of bone metastasis. Cold Spring Harb Perspect Med. 2018; 8(6):A031252.

[6] RoodmanGD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.

[7] WangW, YangX, DaiJ, LuY, ZhangJ, Keller ET. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene. 2019; 38(23):4540-4559.

[8] SoeharnoH, Povegliano L, ChoongPF. Multimodal treatment of bone metastasis—a surgical perspective. Front Endocrinol (Lausanne). 2018; 9:518.

[9] BădilăAE, Rădulescu DM, NiculescuA-G, GrumezescuAM, Rădulescu M, RădulescuAR. Recent advances in the treatment of bone metastases and primary bone tumors: an up-to-date review. Cancer. 2021; 13(16):4229.

[10] KrishnanCK, KimH-S, YunJY, Cho HS, ParkJW, HanI. Factors associated with local recurrence after surgery for bone metastasis to the extremities. J Surg Oncol. 2018; 117(4):797-804.

[11] ZhuH, LuoH, ZhangW, Shen Z, HuX, ZhuX. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016; 10:1885-1895.

[12] AgnelloL, Tortorella S, d’ArgenioA, et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. J Exp Clin Cancer Res. 2021; 40(1):239.

[13] ZhangB, ZhangY, LiR, LiJ, LuX, ZhangY. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis. J Orthop Surg Res. 2020; 15(1):51.

[14] MiyazakiJ, KawaiK, HayashiH, et al. The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer. Jpn J Clin Oncol. 2003; 33(8):391-395.

[15] MengJ, GuQP, MengQF, et al. Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. Cell Biochem Biophys. 2014; 68(1):181-184.

[16] SajjadH, ImtiazS, NoorT, Siddiqui YH, SajjadA, ZiaM. Cancer models in preclinical research: a chronicle review of advancement in effective cancer research. Animal Model Exp Med. 2021; 4(2):87-103.

[17] GilazievaZ, Ponomarev A, RutlandC, RizvanovA, Solovyeva V. Promising applications of tumor spheroids and organoids for personalized medicine. Cancers (Basel). 2020; 12(10):2727.

[18] WalmsleyGG, RansomRC, ZielinsER, et al. Stem cells in bone regeneration. Stem Cell Rev Rep. 2016; 12(5):524-529.

[19] PittengerMF, Discher DE, PéaultBM, PhinneyDG, HareJM, CaplanAI. Mesenchymal stem cell perspective: cell biology to clinical progress. Npj. Regen Med. 2019; 4(1):22.

[20] SenthebaneDA, RoweA, ThomfordNE, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017; 18(7):1586.

[21] VisMAM, ItoK, HofmannS. Impact of culture medium on cellular interactions in in vitro co-culture systems. Front Bioeng Biotechnol. 2020; 8:911.

[22] MugurumaM, Teraoka S, MiyaharaK, et al. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines. Biochem Biophys Res Commun. 2020; 533(3):268-274.

[23] GraysonKA, Jyotsana N, Ortiz-OteroN, KingMR. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes. PLoS One. 2021; 16(3):e0246733.

[24] HuangZ, YuP, TangJ. Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. Onco Targets Ther. 2020; 13:5395-5405.

[25] ChambersKF, MosaadEMO, RussellPJ, Clements JA, DoranMR. 3D cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One. 2014; 9(11):e111029.

[26] BreslinS, O’Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget. 2016; 7(29):45745-45756.

[27] LovittCJ, Shelper TB, AveryVM. Evaluation of chemotherapeutics in a three-dimensional breast cancer model. J Cancer Res Clin Oncol. 2015; 141(5):951-959.

[28] GomesLR, RochaCRR, MartinsDJ, et al. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Cell Death Dis. 2019; 10(6):459.

[29] AzimiT, Loizidou M, DwekMV. Cancer cells grown in 3D under fluid flow exhibit an aggressive phenotype and reduced responsiveness to the anti-cancer treatment doxorubicin. Sci Rep. 2020; 10(1):12020.

[30] BrodeurMN, Simeone K, Leclerc-DeslauniersK, et al. Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. Sci Rep. 2021; 11(1):18183.

[31] ZanoniM, Cortesi M, ZamagniA, ArientiC, Pignatta S, TeseiA. Modeling neoplastic disease with spheroids and organoids. J Hematol Oncol. 2020; 13(1):97.

[32] HsiaoAY, Torisawa YS, TungYC, et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials. 2009; 30(16):3020-3027.

[33] YanX-Z, van den Beucken J, YuanC, JansenJ, YangF. Spheroid formation and stemness preservation of human periodontal ligament cells on chitosan films. Oral Dis. 2018; 24(6):1083-1092.

[34] RybkowskaP, Radoszkiewicz K, KawalecM, et al. The metabolic changes between monolayer (2D) and three-dimensional (3D) culture conditions in human mesenchymal stem/stromal cells derived from adipose tissue. Cells. 2023; 12(1):178.

[35] LewisNS, LewisEE, MullinM, Wheadon H, DalbyMJ, BerryCC. Magnetically levitated mesenchymal stem cell spheroids cultured with a collagen gel maintain phenotype and quiescence. J Tissue Eng. 2017; 8:2041731417704428.

[36] FoisMG, Tahmasebi Birgani ZN, GuttenplanAPM, et al. Assessment of cell–material interactions in three dimensions through dispersed coaggregation of microsized biomaterials into tissue spheroids. Small. 2022; 18(29):2202112.

[37] SethakornN, Heninger E, Sánchez-de-DiegoC, et al. Advancing treatment of bone metastases through novel translational approaches targeting the bone microenvironment. Cancers (Basel). 2022; 14(3):757.

[38] Marturano-KruikA, Nava MM, YeagerK, et al. Human bone perivascular niche-on-a-chip for studying metastatic colonization. Proc Natl Acad Sci USA. 2018; 115(6):1256-1261.

[39] HaoS, HaL, ChengG, et al. A spontaneous 3D bone-on-a-chip for bone metastasis study of breast cancer cells. Small. 2018; 14(12):e1702787.

[40] BersiniS, JeonJS, DubiniG, et al. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials. 2014; 35(8):2454-2461.

[41] JeonJS, Bersini S, GilardiM, et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci USA. 2015; 112(1):214-219.

[42] ChoudharyS, Ramasundaram P, DziopaE, et al. Human ex vivo 3D bone model recapitulates osteocyte response to metastatic prostate cancer. Sci Rep. 2018; 8(1):17975.

[43] Mohseni GarakaniM, Cooke ME, WeberMH, WertheimerMR, AjjiA, RosenzweigDH. A 3D, compartmental tumor-stromal microenvironment model of patient-derived bone metastasis. Int J Mol Sci. 2023; 24(1):160.

[44] CuiH, Esworthy T, ZhouX, et al. Engineering a novel 3D printed vascularized tissue model for investigating breast cancer metastasis to bone. Adv Healthc Mater. 2020; 9(15):1900924.

[45] AngeloniV, Contessi N, De MarcoC, et al. Polyurethane foam scaffold as in vitro model for breast cancer bone metastasis. Acta Biomater. 2017; 63:306-316.

[46] PaindelliC, NavoneN, LogothetisCJ, FriedlP, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials. 2019; 197:296-304.

[47] ZhuW, WangM, FuY, CastroNJ, FuSW, ZhangLG. Engineering a biomimetic three-dimensional nanostructured bone model for breast cancer bone metastasis study. Acta Biomater. 2015; 14:164-174.

[48] ZhouX, ZhuW, NowickiM, et al. 3D bioprinting a cell-laden bone matrix for breast cancer metastasis study. ACS Appl Mater Interfaces. 2016; 8(44):30017-30026.

[49] PathiSP, LinDD, DorveeJR, Estroff LA, FischbachC. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials. 2011; 32(22):5112-5122.

[50] MarlowR, HonethG, LombardiS, et al. A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res. 2013; 73(23):6886-6899.

[51] FitzgeraldKA, GuoJ, RafteryRM, et al. Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis. Int J Pharm. 2016; 511(2):1058-1069.

[52] KarS, MollaMS, KattiDR, Katti KS. Tissue-engineered nanoclay-based 3D in vitro breast cancer model for studying breast cancer metastasis to bone. J Tissue Eng Regen Med. 2019; 13(2):119-130.

[53] TaubenbergerAV, QuentVM, ThibaudeauL, Clements JA, HutmacherDW. Delineating breast cancer cell interactions with engineered bone microenvironments. J Bone Miner Res. 2013; 28(6):1399-1411.

[54] ReichertJC, QuentVM, BurkeLJ, Stansfield SH, ClementsJA, HutmacherDW. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials. 2010; 31(31):7928-7936.

[55] LescarbeauRM, SeibFP, PrewitzM, Werner C, KaplanDL. In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors. PLoS One. 2012; 7(8):e40372.

[56] QiaoH, TangT. Engineering 3D approaches to model the dynamic microenvironments of cancer bone metastasis. Bone Res. 2018; 6(1):3.

[57] DecarliMC, AmaralR, SantosDPD, et al. Cell spheroids as a versatile research platform: formation mechanisms, high throughput production, characterization and applications. Biofabrication. 2021; 13(3):032002.

[58] AntunesJ, GasparVM, FerreiraL, et al. In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening. Acta Biomater. 2019; 94:392-409.

[59] TaiS, SunY, SquiresJM, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011; 71(15):1668-1679.

[60] ParkSH, EberMR, ShiozawaY. Models of prostate cancer bone metastasis. Methods Mol Biol. 2019; 1914:295-308.

[61] DeCastroAJL, PrandaMA, GrayKM, et al. Morphological phenotyping of organotropic brain- and bone-seeking triple negative metastatic breast tumor cells. Front Cell Dev Biol. 2022; 10:790410.

[62] MaJ, van den Beucken JJ, BothSK, et al. Osteogenic capacity of human BM-MSCs, AT-MSCs and their co-cultures using HUVECs in FBS and PL supplemented media. J Tissue Eng Regen Med. 2015; 9(7):779-788.

[63] DominiciM, Le Blanc K, MuellerI, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-317.

[64] SchindelinJ, Arganda-Carreras I, FriseE, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-682.

[65] MiharaH, KugawaM, SayoK, et al. Improved oxygen supply to multicellular spheroids using a gas-permeable plate and embedded hydrogel beads. Cells. 2019; 8(6):525.

[66] OllionJ, Cochennec J, LollF, EscudéC, Boudier T. TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics. 2013; 29(14):1840-1841.

[67] VindinH, Bischof L, GunningP, StehnJ. Validation of an algorithm to quantify changes in Actin cytoskeletal organization. SLAS Discov. 2014; 19(3):354-368.

[68] KellerF, RudolfR, HafnerM. Towards optimized breast cancer 3D spheroid mono- and co-culture models for pharmacological research and screening. J Cell Biotechnol. 2019; 5:89-101.

[69] RaghavanS, MehtaP, HorstEN, Ward MR, RowleyKR, MehtaG. Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity. Oncotarget. 2016; 7(13):16948-16961.

[70] LeungBM, Lesher-Perez SC, MatsuokaT, MoraesC, Takayama S. Media additives to promote spheroid circularity and compactness in hanging drop platform. Biomater Sci. 2015; 3(2):336-344.

[71] KuoC-T, WangJ-Y, LinY-F, Wo AM, ChenBPC, LeeH. Three-dimensional spheroid culture targeting versatile tissue bioassays using a PDMS-based hanging drop array. Sci Rep. 2017; 7(1):4363.

[72] SchmitzC, Potekhina E, IriantoT, BelousovVV, Lavrentieva A. Hypoxia onset in mesenchymal stem cell spheroids: monitoring with hypoxia reporter cells. Front Bioeng Biotechnol. 2021; 9:611837.

[73] MurphyKC, HungBP, Browne-BourneS, et al. Measurement of oxygen tension within mesenchymal stem cell spheroids. J R Soc Interface. 2017; 14(127):20160851.

[74] SinghSK, AbbasS, SaxenaAK, Tiwari S, SharmaLK, TiwariM. Critical role of three-dimensional tumorsphere size on experimental outcome. Biotechniques. 2020; 69(5):333-338.

[75] MukomotoR, Nashimoto Y, TeraiT, et al. Oxygen consumption rate of tumour spheroids during necrotic-like core formation. Analyst. 2020; 145(19):6342-6348.

[76] CostardLS, HosnRR, RamanayakeH, O’Brien FJ, CurtinCM. Influences of the 3D microenvironment on cancer cell behaviour and treatment responsiveness: a recent update on lung, breast and prostate cancer models. Acta Biomater. 2021;132:360-378.

[77] LarangaR, DuchiS, IbrahimT, Guerrieri AN, DonatiDM, LucarelliE. Trends in bone metastasis modeling. Cancers (Basel). 2020; 12(8):2315.

[78] PoornimaK, Francis AP, HodaM, et al. Implications of three-dimensional cell culture in cancer therapeutic research. Front Oncol. 2022; 12:891673.

[79] TsaiAC, LiuY, YuanX, Ma T. Compaction, fusion, and functional activation of three-dimensional human mesenchymal stem cell aggregate. Tissue Eng Part A. 2015; 21(9-10):1705-1719.

[80] SaraivaDP, MatiasAT, BragaS, Jacinto A, CabralMG. Establishment of a 3D Co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies. Front Oncol. 2020; 10:1543.

[81] CavacoM, FragaP, ValleJ, Andreu D, CastanhoM, NevesV. Development of breast cancer spheroids to evaluate cytotoxic response to an anticancer peptide. Pharmaceutics. 2021; 13(11):1863.

[82] DangPN, Dwivedi N, YuX, et al. Guiding chondrogenesis and osteogenesis with mineral-coated hydroxyapatite and BMP-2 incorporated within high-density hMSC aggregates for bone regeneration. ACS Biomater Sci Eng. 2016; 2(1):30-42.

[83] TaqiSA, SamiSA, SamiLB, Zaki SA. A review of artifacts in histopathology. J Oral Maxillofac Pathol. 2018; 22(2):279.

[84] MandelK, YangY, SchambachA, Glage S, OtteA, HassR. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo. Stem Cells Dev. 2013; 22(23):3114-3127.

[85] LiQ, RycajK, ChenX, Tang DG. Cancer stem cells and cell size: a causal link? Semin Cancer Biol. 2015; 35:191-199.

[86] DoğanA, Demirci S, ApdikH, ApdikEA, Şahin F. Mesenchymal stem cell isolation from pulp tissue and co-culture with cancer cells to study their interactions. J Vis Exp. 2019; 7(143):e58825. doi:doi:10.3791/58825

[87] ChongMS, LimJ, GohJ, SiaMW, ChanJK, Teoh SH. Cocultures of mesenchymal stem cells and endothelial cells as organotypic models of prostate cancer metastasis. Mol Pharm. 2014; 11(7):2126-2133.

[88] BartoshTJ, UllahM, ZeitouniS, Beaver J, ProckopDJ. Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proc Natl Acad Sci USA. 2016; 113(42):E6447-e6456.

[89] FaisS, Overholtzer M. Cell-in-cell phenomena, cannibalism, and autophagy: is there a relationship? Cell Death Dis. 2018; 9(2):95.

[90] SiehS, Taubenberger AV, LehmanML, ClementsJA, NelsonCC, HutmacherDW. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone. 2014; 63:121-131.

[91] AravindhanS, EjamSS, LaftaMH, Markov A, YumashevAV, AhmadiM. Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature. Cancer Cell Int. 2021; 21(1):158.

[92] LeeHY, HongIS. Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential. Cancer Sci. 2017; 108(10):1939-1946.

[93] XuanX, TianC, ZhaoM, Sun Y, HuangC. Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance. Cancer Cell Int. 2021; 21(1):595.

[94] YonedaT, HiasaM, NagataY, Okui T, WhiteF. Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochim Biophys Acta. 2015; 1848(10):2677-2684.

[95] AvnetS, Di Pompo G, LemmaS, BaldiniN. Cause and effect of microenvironmental acidosis on bone metastases. Cancer Metastasis Rev. 2019; 38(1):133-147.

[96] MosaadE, Chambers K, FutregaK, ClementsJ, DoranMR. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures. BMC Cancer. 2018; 18(1):592.

[97] Duś-SzachniewiczK, Gdesz-BirulaK, Rymkiewicz G. Development and characterization of 3D hybrid spheroids for the investigation of the crosstalk between B-cell non-hodgkin lymphomas and mesenchymal stromal cells. Onco Targets Ther. 2022; 15:683-697.

[98] FotyRA, Steinberg MS. The differential adhesion hypothesis: a direct evaluation. Dev Biol. 2005; 278(1):255-263.

[99] FotyRA, Steinberg MS. Differential adhesion in model systems. Wiley Interdiscip Rev Dev Biol. 2013; 2(5):631-645.

[100] KaszakI, Witkowska-Piłaszewicz O, NiewiadomskaZ, Dworecka-KaszakB, Ngosa Toka F, JurkaP. Role of cadherins in cancer—a review. Int J Mol Sci. 2020; 21(20):7624.

[101] SmrkeA, Anderson PM, GuliaA, GennatasS, HuangPH, JonesRL. Future directions in the treatment of osteosarcoma. Cells. 2021; 10(1):172.

[102] PoggioF, Bruzzone M, CeppiM, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018; 29(7):1497-1508.

[103] ChouF-J, LinC, TianH, et al. Preclinical studies using cisplatin/carboplatin to restore the enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress enzalutamide resistant prostate cancer. Cell Death Dis. 2020; 11(11):942.

[104] ShaoH, Varamini P. Breast cancer bone metastasis: a narrative review of emerging targeted drug delivery systems. Cells. 2022; 11(3):388.

[105] YuY, SunL, TangY, et al. Preparation of cisplatin delivery calcium phosphate nanoparticles using poly(Pt(IV) prodrug) as the payload. Mater Today Commun. 2022; 33:104283.

[106] ZakeriN, RezaieHR, JavadpourJ, Kharaziha M. Cisplatin loaded polycaprolactone—zeolite nanocomposite scaffolds for bone cancer treatment. J Sci Adv Mater Devices. 2021;7:100377.

[107] BarbanenteA, GandinV, DitarantoN, et al. A Pt(IV) prodrug of kiteplatin with the bone-targeting pyrophosphate ligand. Inorg Chim Acta. 2019; 494:98-104.

[108] WangS, XieJ, LiJ, LiuF, WuX, WangZ. Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin β5-mediated glycolysis. Am J Cancer Res. 2016; 6(5):1108-1117.

[109] BaekN, SeoOW, LeeJ, HulmeJ, AnSS. Real-time monitoring of cisplatin cytotoxicity on three-dimensional spheroid tumor cells. Drug Des Devel Ther. 2016; 10:2155-2165.

[110] BarbanenteA, NadarRA, EspostiLD, et al. Platinum-loaded, selenium-doped hydroxyapatite nanoparticles selectively reduce proliferation of prostate and breast cancer cells co-cultured in the presence of stem cells. J Mater Chem B. 2020; 8(14):2792-2804.

[111] NadarRA, AsokanN, Degli EspostiL, et al. Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model. Nanoscale. 2020; 12(25):13582-13594.

[112] WangZ, Nogueira LP, HaugenHJ, et al. Dual-functional porous and cisplatin-loaded polymethylmethacrylate cement for reconstruction of load-bearing bone defect kills bone tumor cells. Bioact Mater. 2022; 15:120-130.

[113] BhatavdekarO, GodetI, GilkesD, Sofou S. The rate of cisplatin dosing affects the resistance and metastatic potential of triple negative breast cancer cells, independent of hypoxia. Pharmaceutics. 2022; 14(10):2184.

[114] AtaFK, YalcinS. The cisplatin, 5-fluorouracil, irinotecan, and gemcitabine treatment in resistant 2D and 3D model triple negative breast cancer cell line: ABCG2 expression data. Anti Cancer Agents Med Chem. 2022; 22(2):371-377.

[115] MalhãoF, RamosAA, MacedoAC, Rocha E. Cytotoxicity of seaweed compounds, alone or combined to reference drugs, against breast cell lines cultured in 2D and 3D. Toxics. 2021; 9(2):24.

[116] MalhãoF, MacedoAC, CostaC, Rocha E, RamosAA. Fucoxanthin holds potential to become a drug adjuvant in breast cancer treatment: evidence from 2D and 3D cell cultures. Molecules [Internet]. 2021; 26(14):4288.

[117] BoccellinoM, Ambrosio P, BalliniA, et al. The role of curcumin in prostate cancer cells and derived spheroids. Cancers (Basel). 2022; 14(14):3348.

[118] GoldJM, RajaA. Cisplatin. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023. StatPearls Publishing LLC; 2023.

[119] HuangH. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors (Basel). 2018; 18(10):32-49.

[120] HolenI, NutterF, WilkinsonJM, Evans CA, AvgoustouP, OttewellPD. Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clin Exp Metastasis. 2015; 32(7):689-702.

[121] SiehS, LubikAA, ClementsJA, Nelson CC, HutmacherDW. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis. 2010; 6(3):181-188.

[122] YousefEM, TahirMR, St-PierreY, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 2014; 14:609.

[123] BockN, KryzaT, ShokoohmandA, et al. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci Adv. 2021; 7(27):eabg2564.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.